New On Robinhood

Taysha Gene Therapies

$29.58
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.88 (+3.07%) Today
$0.00 (0.00%) As of 9:00 PM UTC after-hours

Why Robinhood?

You can buy or sell TSHA and other stocks, options, and ETFs commission-free!

About TSHA

Taysha Gene Therapies, Inc. engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II on September 20, 2019 and is headquartered in Dallas, TX. The listed name for TSHA is Taysha Gene Therapies, Inc. Common Stock.

CEO
R. A. Session
Employees
—
Headquarters
Dallas, Texas
Founded
—
Market Cap
1.08B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
139.60K
High Today
$30.00
Low Today
$27.80
Open Price
$28.67
Volume
58.51K
52 Week High
$30.96
52 Week Low
$18.16

Collections

TSHA Earnings

-$1.28
-$0.85
-$0.43
$0.00
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 15, After Hours

You May Also Like

UZB
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure